BioPharma Resources

Drug Trial Radar · NCT04546009

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 992 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

992

Actual

Start

Oct 9, 2020

Primary completion

Jan 30, 2026

Study completion Jul 28, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

Conditions

  • Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Interventions

  • GiredestrantDrug

    Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • Giredestrant-matched PlaceboDrug

    Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • LetrozoleDrug

    Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • Letrozole-matched PlaceboDrug

    Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.

  • PalbociclibDrug

    Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.

  • LHRH AgonistDrug

    Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)

Locations

256 sites in 30 countries. Site status is shown where the registry gives one.

  • Orange Coast Memorial Medical Center

    Fountain Valley, California

  • Long Beach Memorial Medical Center

    Long Beach, California

  • Kaiser Permanente - San Leandro Medical Center

    San Leandro, California

  • Stanford Univ Medical Center

    Stanford, California

  • Kaiser Permanente - Walnut Creek

    Walnut Creek, California

  • University of Colorado

    Aurora, Colorado

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Florida Cancer Specialists - Fort Myers (Broadway)

    Fort Myers, Florida

  • Memorial Regional Cancer Ctr

    Hollywood, Florida

  • University of Miami

    Miami, Florida

  • SCRI Florida Cancer Specialists North

    St. Petersburg, Florida

  • SCRI Florida Cancer Specialists PAN

    Tallahassee, Florida

  • Kaiser Permanente - Moanalua Medical Center

    Honolulu, Hawaii

  • Mercy Medical Center

    Baltimore, Maryland

  • Maryland Oncology Hematology

    Silver Spring, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • HCA Midwest Division

    Kansas City, Missouri

  • Memorial Sloan Kettering Cancer Center Basking Ridge

    Basking Ridge, New Jersey

  • Astera Cancer Care East Brunswick

    East Brunswick, New Jersey

  • Memorial Sloan Kettering Cancer Center at Bergen

    Montvale, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • MSKCC @ Commack

    Commack, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Providence Portland Medical Ctr

    Portland, Oregon

  • Roper St. Francis Healthcare

    Charleston, South Carolina

  • West Cancer Center

    Germantown, Tennessee

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology - DFW

    Dallas, Texas

  • The Center for Cancer and Blood Disorders - Fort Worth

    Fort Worth, Texas

  • Baylor St. Luke's Medical Center

    Houston, Texas

  • Houston Methodist Hospital

    Houston, Texas

  • Inova Fairfax Hospital

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Northwest Medical Specialties

    Tacoma, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Hospital de Onc Angel Roffo

    Buenos Aires, Argentina

  • Organización medica de Investi

    Cap Fed, Argentina

Showing 40 of 256 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.